{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-24-000010","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.105372+00:00","generated_at":"2026-06-05T19:37:10.238983+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moderna Q4 2023 revenue $2.8B, EPS $0.55; FY net loss $4.7B from $3.7B non-cash charges","bullets":["Q4 revenue $2.8B (-43% YoY); GAAP net income $217M, diluted EPS $0.55.","FY2023 revenue $6.8B; GAAP net loss $4.7B, diluted EPS ($12.33) from $3.7B non-cash charges (resizing, valuation allowance).","Reaffirms 2024 product sales ~$4B; expects RSV vaccine (mRNA-1345) regulatory approvals beginning H1 2024 (PDUFA May 12).","FY2023 COVID vaccine sales $6.7B; U.S. retail market share 48% (vs 37% in 2022).","2024 guidance: cost of sales ~35% of product sales; R&D ~$4.5B; SG&A ~$1.3B; year-end cash ~$9B."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-24-000010","json":"https://secwatch.observer/filing/0001682852-24-000010.json","markdown":"https://secwatch.observer/filing/0001682852-24-000010.md","text":"https://secwatch.observer/filing/0001682852-24-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000010/0001682852-24-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000010/mrna-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:37:10.238983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6f82fbe56430cc2e5cf32cceab090c4baa0b5b4","claim":"Moderna, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $2.8 billion, net income $217 million, EPS $0.55. Guidance reaffirmed.","evidence_excerpt":"Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000010/0001682852-24-000010-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$2.8 billion"},{"label":"Net income","value":"$217 million"},{"label":"EPS","value":"$0.55"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}